AstraZeneca Allies with Cansino to Enter Messenger RNA Therapies

AstraZeneca has decided to enter the business of developing Message RNA therapies, allying with the Chinese pharmaceutical company, Cansino. The British multinational has reached an agreement with the Asian company that will last for the next ten years for it to provide and supply future therapies, according to the press release issued by Cansino.

The cooperation between the two companies will focus on the use of the Chinese company’s messenger RNA production platform to support its research and development of targeted vaccines.

Cansino uses self-designed and developed sequence optimization software, which can obtain key sites that affect stability and optimal sequences that can effectively improve antigen expression for the development of these therapies.

If you want to find more details about the agreement between AstraZeneca and Cansino and to read the latest business news of the day, download for free our companion app Born2Invest, available for free, for both Android and iOS devices.

AstraZeneca has signed an agreement for the next ten years with Cansino

From the Chinese pharmaceutical company, they emphasize that this agreement is an important sign that the company’s capabilities are recognized by international pharmaceutical companies and the competitive advantages in the Messenger RNA technology platform.

Currently, the British multinational does not have any project related to this type of therapy. AstraZeneca tried to reach this market through a negotiation with Moderna, but in the end, no agreement was reached.

Recently, the British multinational acquired Pfizer’s gene therapy portfolio for one billion dollars. AstraZeneca took a new step to increase and diversify its product portfolio and has reached an agreement with the US multinational to take over these drugs in the investigational phase while agreeing with payments on the future sale of products.

AstraZeneca has multiplied its profit by five in the first quarter of this year, up to 2,181 million dollars, five times more than in the same period of 2022. However, billing fell 4.49%, to 10,879 million dollars, with a drop of 1,460 million dollars in medicines related to Covid-19. Oncology drugs increased between 19% and 14%.

AstraZeneca is a British biopharmaceutical company focused on the discovery, development, and commercialization of prescription drugs. The company was founded in 1999 as a result of the merger of the Swedish laboratory Astra AB and the British pharmaceutical company Zeneca Group.

__

(Featured image by THAVIS 3D via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.